NRG
ABBV icon

Nemes Rush Group’s AbbVie ABBV Stock Holding History

Nemes Rush Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.01M Sell
15,922
-89
-0.6% -$19.1K 0.33% 60
2026
Q1 		$3.48M Buy
16,011
+153
+1% +$33.9K 0.33% 63
2025
Q4 		$3.62M Buy
15,858
+157
+1% +$35.8K 0.34% 61
2025
Q3 		$3.64M Buy
15,701
+921
+6% +$188K 0.36% 55
2025
Q2 		$2.74M Buy
14,780
+11,440
+343% +$2.13M 0.3% 62
2025
Q1 		$700K Sell
3,340
-378
-10% -$73.5K 0.09% 107
2024
Q4 		$661K Sell
3,718
-417
-10% -$76.7K 0.08% 108
2024
Q3 		$753K Buy
4,135
+244
+6% +$45.5K 0.11% 100
2024
Q2 		$667K Sell
3,891
-295
-7% -$48.9K 0.09% 105
2024
Q1 		$762K Sell
4,186
-96
-2% -$16.5K 0.11% 100
2023
Q4 		$664K Sell
4,282
-747
-15% -$109K 0.11% 113
2023
Q3 		$750K Sell
5,029
-1,663
-25% -$244K 0.14% 101
2023
Q2 		$902K Buy
+6,692
New +$981K 0.16% 90

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Nemes Rush Group's ABBV Position: Q2 2026 in Review

Nemes Rush Group reduced its AbbVie (ABBV) stake by 0.56% in Q2 2026, selling an estimated $19.1K and leaving 15,922 shares worth $4.01M. The position accounts for 0.33% of the portfolio, ranked #60.

Nemes Rush Group first reported a position in ABBV in Q2 2023 and has held it in 13 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nemes Rush Group held 15,922 shares of AbbVie worth $4.01M as of Q2 2026.
  • Nemes Rush Group sold 89 AbbVie shares in Q2 2026, an estimated $19.1K.
  • AbbVie made up 0.33% of Nemes Rush Group's portfolio in Q2 2026, its #60 holding.
  • Nemes Rush Group first reported a position in AbbVie in Q2 2023 and has held it in 13 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.